Patents by Inventor Syed M. Shah

Syed M. Shah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240050377
    Abstract: Cannabinoid oil compositions may be used to treat central nervous system disorders. An example of the composition is an oral multiparticulate dosage form including a plurality of individual particulates including a solid core with an effective amount of cannabinoid oil bound in microcrystalline cellulose therein and an enteric coating over the solid core.
    Type: Application
    Filed: December 23, 2021
    Publication date: February 15, 2024
    Inventor: SYED M. SHAH
  • Patent number: 11896721
    Abstract: An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain a solid core containing the L-carnitine, and an enteric coating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: February 13, 2024
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Noreen Hassan
  • Publication number: 20230414490
    Abstract: The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.
    Type: Application
    Filed: September 11, 2023
    Publication date: December 28, 2023
    Applicant: Wyeth, LLC
    Inventors: Syed M. Shah, Christian Ofslager, Mahdi B. Fawzi, Nataliya Bazhina
  • Patent number: 11826475
    Abstract: A method of treating a gastrointestinal disorder includes administering to a patient an effective amount of a multiparticulate dosage form including a plurality of individual spheroidal enteric coated cores having a diameter of 0.1 mm to 3 mm. The individual spheroidal enteric coated cores have (a) a core including menthol, (b) a proteinaceous subcoating over the core, and (c) an enteric coating over the proteinaceous subcoating. The multiparticulate dosage form is configured to release most of the menthol in the area of the GI tract where the inflammation is occurring.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: November 28, 2023
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Fred Hassan
  • Patent number: 11779547
    Abstract: An L-menthol pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core and an enteric coating over the core. The core includes an L-menthol source that is at least 80% pure L-menthol. The dosage form may be used to treat gastrointestinal disorders, such as irritable bowel syndrome.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: October 10, 2023
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan
  • Patent number: 11723862
    Abstract: A composition comprises a therapeutically effective oral pharmaceutical dosage form. The dosage form includes an aqueous carrier material having an acidic pH and a plurality of individual pellets having a first dose of melatonin therein. The individual pellets comprises (i) a solid core; (ii) an active coating over the solid core, the active coating including melatonin and a hydrophilic binder; and (iii) an enteric coating over the active coating. A dissolution pH of the enteric coating is higher than the acidic pH of the aqueous carrier material.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: August 15, 2023
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Syed M. Shah, Daniel Hassan
  • Patent number: 11717494
    Abstract: Cannabinoid oil compositions may be used to treat gastrointestinal disorders. An example of the composition is an oral multiparticulate dosage form including a plurality of individual particulates including a solid core with an effective amount of cannabinoid oil bound in microcrystalline cellulose therein and an enteric coating over the solid core.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: August 8, 2023
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Syed M. Shah, Fred Hassan
  • Patent number: 11701425
    Abstract: A valerian composition includes valerian and an acidifying agent blended together in a pharmaceutically acceptable hydrogel-forming polymer matrix. An expedited release portion of the dosage form includes 5% to 50% of the valerian and is effective to release the valerian therein within 2 hours from placement in a 0.1 N HCl solution. A sustained release portion of the dosage form includes the remainder of the valerian and is effective to release the valerian therein within 10 hours from placement in a phosphate buffer with a pH of 6.8.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: July 18, 2023
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Christopher Diorio, Daniel Hassan, Fred Hassan
  • Publication number: 20230065736
    Abstract: Cannabinoid oil compositions may be used to treat gastrointestinal disorders. An example of the composition is an oral multiparticulate dosage form including a plurality of individual particulates including a solid core with an effective amount of cannabinoid oil bound in microcrystalline cellulose therein and an enteric coating over the solid core.
    Type: Application
    Filed: January 8, 2021
    Publication date: March 2, 2023
    Inventors: SYED M. SHAH, FRED HASSAN
  • Publication number: 20230045118
    Abstract: A composition comprises a therapeutically effective oral pharmaceutical dosage form. The dosage form includes an aqueous carrier material having an acidic pH and a plurality of individual pellets having a first dose of melatonin therein. The individual pellets comprises (i) a solid core; (ii) an active coating over the solid core, the active coating including melatonin and a hydrophilic binder; and (iii) an enteric coating over the active coating. A dissolution pH of the enteric coating is higher than the acidic pH of the aqueous carrier material.
    Type: Application
    Filed: January 15, 2021
    Publication date: February 9, 2023
    Inventors: SYED M. SHAH, DANIEL HASSAN
  • Patent number: 11389428
    Abstract: An oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin includes melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: July 19, 2022
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan
  • Publication number: 20220079921
    Abstract: A melatonin composition has a dry granulation including a melatonin powder with a median melatonin particle size of 5 ?m to 40 ?m, a carboxylic acid powder, and a powder of a hydrogel-forming polymer. The dry granulation is combined with pharmaceutical excipients in a dry orally ingestible pharmaceutical dosage form adapted to absorb water upon ingestion and form a hydrogel including soluble melatonin and soluble carboxylic acid in the hydrogel, the carboxylic acid being in an amount sufficient to impart a pH of 4.4 or less to the hydrogel after ingestion.
    Type: Application
    Filed: January 17, 2020
    Publication date: March 17, 2022
    Inventors: Syed M. Shah, Daniel Hassan
  • Publication number: 20220071912
    Abstract: A method of treating a gastrointestinal disorder includes administering to a patient an effective amount of a multiparticulate dosage form including a plurality of individual spheroidal enteric coated cores having a diameter of 0.1 mm to 3 mm. The individual spheroidal enteric coated cores have (a) a core including menthol, (b) a proteinaceous subcoating over the core, and (c) an enteric coating over the proteinaceous subcoating. The multiparticulate dosage form is configured to release most of the menthol in the area of the GI tract where the inflammation is occurring.
    Type: Application
    Filed: November 17, 2021
    Publication date: March 10, 2022
    Inventors: Syed M. Shah, Fred Hassan
  • Publication number: 20220023200
    Abstract: The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 27, 2022
    Applicant: Wyeth, LLC
    Inventors: Syed M. Shah, Christian Ofslager, Mahdi B. Fawzi, Nataliya Bazhina
  • Patent number: 11224657
    Abstract: A composition includes a pharmaceutical tablet dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: January 18, 2022
    Assignee: Société des Produits Nestlé S. A.
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Patent number: 11224658
    Abstract: A composition includes a pharmaceutical dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: January 18, 2022
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Publication number: 20210401990
    Abstract: A valerian composition includes valerian and an acidifying agent blended together in a pharmaceutically acceptable hydrogel-forming polymer matrix. An expedited release portion of the dosage form includes 5% to 50% of the valerian and is effective to release the valerian therein within 2 hours from placement in a 0.1 N HCl solution. A sustained release portion of the dosage form includes the remainder of the valerian and is effective to release the valerian therein within 10 hours from placement in a phosphate buffer with a pH of 6.8.
    Type: Application
    Filed: September 8, 2021
    Publication date: December 30, 2021
    Inventors: Syed M. Shah, Christopher Diorio, Daniel Hassan, Fred Hassan
  • Patent number: 11207273
    Abstract: A method of making an L-menthol dosage form includes forming a wet granulation including an L-menthol source and at least one pharmaceutical excipient. The wet granulation is extruded into an extrudate and the extrudate is cut into individual core pieces. The individual core pieces are spheronized into individual spheronized cores and the individual spheronized cores are dried to form dried individual spheronized cores. The dried individual spheronized cores are spray coated with a liquid proteinaceous material that forms a film of a proteinaceous material over the dried individual spheronized cores. The film of proteinaceous material is dried over the dried individual spheronized cores to form individual subcoated cores. An enteric coating is applied and dried over the individual subcoated cores to form a plurality of individual enteric coated cores.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: December 28, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Fred Hassan
  • Patent number: 11208247
    Abstract: Melatonin tablets with a high concentration of citric acid are packaged in a blister package that enhances storage stability. Such a packaging material includes a blister film forming a cavity holding the tablet therein. The blister film includes a polyvinyl chloride (PVC) film having a thickness of 180 ?m to 270 ?m coated with a polyvinylidene chloride (PVDC) coating having a coating weight of 110 g/m2 to 130 g/m2. An aluminum foil lid closes the cavity and encapsulates the tablet within the blister film and lid. The lid has a thickness of 20 ?m to 30 ?m.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: December 28, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan
  • Patent number: 11207276
    Abstract: A pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core including crystalline L-menthol dissolved in a terpene-based essential oil. A proteinaceous coating of a continuous film of proteinaceous material is over the core.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: December 28, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Fred Hassan, Daniel Hassan, Sarah Hassan